Fulcrum Therapeutics (FULC) Short Interest Ratio & Short Volume → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free FULC Stock Alerts $9.44 -0.02 (-0.21%) (As of 03/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Fulcrum Therapeutics Short Interest DataCurrent Short Volume2,390,000 sharesPrevious Short Volume3,200,000 sharesChange Vs. Previous Month-25.31%Dollar Volume Sold Short$27.15 millionShort Interest Ratio / Days to Cover3.4Last Record DateMarch 15, 2024Outstanding Shares61,940,000 sharesPercentage of Shares Shorted3.86%Today's Trading Volume554,392 sharesAverage Trading Volume825,229 sharesToday's Volume Vs. Average67% Short Selling Fulcrum Therapeutics ? Sign up to receive the latest short interest report for Fulcrum Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatFULC Short Interest Over TimeFULC Days to Cover Over TimeFULC Percentage of Float Shorted Over Time Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. Fulcrum Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/20242,390,000 shares $27.15 million -25.3%N/A3.4 $11.36 2/29/20243,200,000 shares $32.67 million -0.6%N/A4.5 $10.21 2/15/20243,220,000 shares $30.27 million -4.7%N/A5.1 $9.40 1/31/20243,380,000 shares $24.40 million -16.3%N/A5.5 $7.22 1/15/20244,040,000 shares $28.68 million +10.1%N/A6.7 $7.10 12/31/20233,670,000 shares $24.77 million +10.2%N/A6.5 $6.75 Get the Latest News and Ratings for FULC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/15/20233,330,000 shares $17.95 million -18.0%N/A6.2 $5.39 11/30/20234,060,000 shares $19.49 million +9.7%N/A7.8 $4.80 11/15/20233,700,000 shares $15.47 million -6.3%N/A6.1 $4.18 10/31/20233,950,000 shares $14.38 million +1.0%N/A2 $3.64 10/15/20233,910,000 shares $15.21 million -2.7%N/A1.9 $3.89 9/30/20234,020,000 shares $17.85 million +7.5%N/A2 $4.44 9/15/20233,740,000 shares $16.79 million +5.1%N/A1.8 $4.49 8/31/20233,560,000 shares $19.69 million +30.4%N/A1.7 $5.53 8/15/20232,730,000 shares $11.55 million -22.2%N/A1.3 $4.23 7/31/20233,510,000 shares $13.41 million +0.3%N/A5 $3.82 7/15/20233,500,000 shares $12.88 million -4.1%N/A4.6 $3.68 6/30/20233,650,000 shares $12.05 million -19.3%N/A4.6 $3.30 6/15/20234,520,000 shares $13.74 million +9.4%N/A5.3 $3.04 5/31/20234,130,000 shares $11.23 million +4.8%N/A4.1 $2.72 5/15/20233,940,000 shares $14.34 million -17.6%N/A3.2 $3.64 4/30/20234,780,000 shares $11.95 million -6.6%N/A3.9 $2.50 4/15/20235,120,000 shares $12.34 million +3.6%N/A4.2 $2.41 3/31/20234,940,000 shares $14.08 million +25.1%N/A3.8 $2.85 3/15/20233,950,000 shares $15.01 million -2.5%N/A3.1 $3.80 2/28/20234,050,000 shares $24.46 million +7.7%N/A3.8 $6.04 2/15/20233,760,000 shares $48.69 million +6.2%N/A3.8 $12.95 1/31/20233,540,000 shares $44.64 million +6.6%N/A4.6 $12.61 1/15/20233,320,000 shares $45.48 million -7.3%N/A4.6 $13.70 12/30/20223,580,000 shares $26.06 million +21.0%N/A5.7 $7.28 12/15/20222,960,000 shares $16.22 million -9.2%N/A6.1 $5.48 11/30/20223,260,000 shares $22.33 million -4.4%N/A8.5 $6.85 11/15/20223,410,000 shares $24.48 million -2.0%N/A8.9 $7.18 10/31/20223,480,000 shares $19.35 million +0.6%N/A8 $5.56 10/15/20223,460,000 shares $25.95 million -3.9%N/A7.5 $7.50 9/30/20223,600,000 shares $29.12 million -7.2%N/A8.4 $8.09 9/15/20223,880,000 shares $35.31 million +13.8%N/A8.4 $9.10 8/31/20223,410,000 shares $25.23 million +5.3%N/A5.3 $7.40 8/15/20223,240,000 shares $25.34 million -8.2%N/A4.6 $7.82 7/31/20223,530,000 shares $20.76 million -6.1%12.0%4.8 $5.88Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> FULC Short Interest - Frequently Asked Questions What is Fulcrum Therapeutics' current short interest? Short interest is the volume of Fulcrum Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 2,390,000 shares of FULC short. Learn More on Fulcrum Therapeutics' current short interest. What is a good short interest ratio for Fulcrum Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FULC shares currently have a short interest ratio of 3.0. Learn More on Fulcrum Therapeutics's short interest ratio. Which institutional investors are shorting Fulcrum Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Fulcrum Therapeutics: Citadel Advisors LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Fulcrum Therapeutics' short interest increasing or decreasing? Fulcrum Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 2,390,000 shares, a decline of 25.3% from the previous total of 3,200,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Fulcrum Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Fulcrum Therapeutics: ALX Oncology Holdings Inc. (10.70%), Travere Therapeutics, Inc. (13.23%), COMPASS Pathways plc (5.09%), GH Research PLC (4.47%), AnaptysBio, Inc. (17.86%), SIGA Technologies, Inc. (13.70%), Biomea Fusion, Inc. (40.61%), Cogent Biosciences, Inc. (9.27%), Mersana Therapeutics, Inc. (7.20%), Phibro Animal Health Co. (4.23%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short Fulcrum Therapeutics stock? Short selling FULC is an investing strategy that aims to generate trading profit from Fulcrum Therapeutics as its price is falling. FULC shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Fulcrum Therapeutics? A short squeeze for Fulcrum Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of FULC, which in turn drives the price of the stock up even further. How often is Fulcrum Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FULC, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: ALX Oncology Short Interest Data Travere Therapeutics Short Interest Data COMPASS Pathways Short Interest Data GH Research Short Interest Data AnaptysBio Short Interest Data SIGA Technologies Short Interest Data Biomea Fusion Short Interest Data Cogent Biosciences Short Interest Data Mersana Therapeutics Short Interest Data Phibro Animal Health Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:FULC) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company